Our "Using the Carcinogenicity Potency Categorization Algorithm to Predict N-Nitrosamine Carcinogenicity" webcast is now available for you to access anytime, and anywhere.
Join the journey with us by visiting
one of our bi-weekly industry Blogs
Powerful study management updates provide cutting-edge digital pathology capabilities.
Advance™ technology-enabled solution enables R&D organizations to cut study timelines, deliver cost savings and reduce animal experimentation.
Healthcare investment specialist ARCHIMED has the expertise, experience, enthusiasm and financial strength to fully back Instem’s ambitions.
© 2024 Instem Group of Companies